神奇制药
(600613)
| 流通市值：31.30亿 | | | 总市值：34.87亿 |
| 流通股本：4.79亿 | | | 总股本：5.34亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 574,528,830.84 | 2,340,945,518 | 1,710,542,948.95 | 1,205,675,056.68 |
| 营业收入 | 574,528,830.84 | 2,340,945,518 | 1,710,542,948.95 | 1,205,675,056.68 |
| 二、营业总成本 | 543,620,372.68 | 2,246,305,246.56 | 1,627,029,203.2 | 1,148,624,617.28 |
| 营业成本 | 291,963,969.03 | 1,172,062,315.51 | 825,029,669.3 | 568,505,034.4 |
| 税金及附加 | 9,990,823.78 | 29,072,794.64 | 22,732,661.92 | 16,494,301.79 |
| 销售费用 | 212,443,264.19 | 909,409,176.86 | 677,563,744.37 | 495,258,748.21 |
| 管理费用 | 18,615,043.03 | 92,534,824.12 | 62,221,345.98 | 41,095,243.56 |
| 研发费用 | 8,960,100.75 | 32,304,982.17 | 31,487,817.57 | 21,258,469.3 |
| 财务费用 | 1,647,171.9 | 10,921,153.26 | 7,993,964.06 | 6,012,820.02 |
| 其中:利息费用 | 3,016,207.09 | 14,763,810.95 | 10,901,474.56 | 7,720,289.65 |
| 其中:利息收入 | 1,461,637.87 | 5,158,763.57 | 3,623,609.35 | 2,366,036.07 |
| 加:公允价值变动收益 | -7,877.97 | 897,679.62 | 571,753.13 | 25,785.95 |
| 加:投资收益 | - | 810,174.97 | - | - |
| 资产处置收益 | 151,917.7 | 268,660.79 | 31,849.7 | -74,554.15 |
| 资产减值损失(新) | - | -72,412,600.81 | -2,093,620.44 | -2,093,620.44 |
| 信用减值损失(新) | 90,360 | 47,685,053.3 | -4,381,435.72 | -4,431,435.72 |
| 其他收益 | 603,356.71 | 10,949,955.1 | 6,333,075.03 | 2,728,077.2 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 31,746,214.6 | 82,839,194.41 | 83,975,367.45 | 53,204,692.24 |
| 加:营业外收入 | 28,453.17 | 931,933.34 | 796,055.3 | 643,729.54 |
| 减:营业外支出 | 389,838.65 | 363,161.24 | 649,333.79 | 175,186.48 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 31,384,829.12 | 83,407,966.51 | 84,122,088.96 | 53,673,235.3 |
| 减:所得税费用 | 6,261,692.49 | 25,148,750.35 | 18,672,240.4 | 19,164,615.69 |
| 六、净利润 | 25,123,136.63 | 58,259,216.16 | 65,449,848.56 | 34,508,619.61 |
| 持续经营净利润 | 25,123,136.63 | 58,259,216.16 | 65,449,848.56 | 34,508,619.61 |
| 归属于母公司股东的净利润 | 23,944,713.73 | 57,000,674.55 | 65,948,566.05 | 34,735,718.51 |
| 少数股东损益 | 1,178,422.9 | 1,258,541.61 | -498,717.49 | -227,098.9 |
| (一)基本每股收益 | 0.04 | 0.11 | 0.12 | 0.06 |
| (二)稀释每股收益 | 0.04 | 0.11 | 0.12 | 0.06 |
| 八、其他综合收益 | 223,699.68 | 4,813,822.44 | 3,669,544.08 | 6,688,730.25 |
| 归属于母公司股东的其他综合收益 | 223,699.68 | 4,813,822.44 | 3,669,544.08 | 6,688,730.25 |
| 九、综合收益总额 | 25,346,836.31 | 63,073,038.6 | 69,119,392.64 | 41,197,349.86 |
| 归属于母公司股东的综合收益总额 | 24,168,413.41 | 61,814,496.99 | 69,618,110.13 | 41,424,448.76 |
| 归属于少数股东的综合收益总额 | 1,178,422.9 | 1,258,541.61 | -498,717.49 | -227,098.9 |
| 公告日期 | 2024-04-30 | 2024-04-30 | 2023-10-31 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |